Who are Switch Therapeutics's investors?

Switch Therapeutics's investors include Insight Partners, UCB, Eli Lilly, Upfront Ventures, Bold Capital Partners, Ono Venture Investment.

When was Switch Therapeutics founded?

Switch Therapeutics was founded in 2020.

Where is Switch Therapeutics headquartered?

Switch Therapeutics is headquartered in South San Francisco, California, United States.

What industry is Switch Therapeutics in?

Switch Therapeutics operates in Life Sciences, Biotech.

How many employees does Switch Therapeutics have?

Switch Therapeutics has 11-50 employees.

Switch Therapeutics

South San Francisco, United States · Founded 2020

Life Sciences

Biotech

Headquarters: South San Francisco, California
Employees: 11–50
Founded: 2020
Business Model: B2B

Website: switchthera.com
Last Round: Series AMar 2023
Rounds: 2

About

Switch Therapeutics is a preclinical-stage biotechnology company founded in 2020 to develop therapeutic applications from RNA interference (RNAi) research pioneered at Caltech, Harvard Medical School, and City of Hope. The company's proprietary CASi (Conditional Activation Switch) platform integrates nucleic acid nanotechnology and RNA biology to create biomarker-gated genetic medicines — therapeutics that activate only in diseased cells expressing specific molecular signals. This programmable, cell-selective approach targets diseases of the central nervous system (CNS) and beyond. Switch raised $52M and moved into its own facility in South San Francisco in early 2022 upon publicly announcing its launch.

Summary

Switch Therapeutics is a Life Sciences company based in South San Francisco, United States, founded in 2020. Its most recent funding was a Series A round in Mar 2023. Investors include Insight Partners, UCB and Eli Lilly.